[三季报]健康元(600380):健康元药业集团股份有限公司2022年第三季度报告（英文版）
|
时间：2022年10月27日 04:38:37 中财网 |
|
原标题:健康元:健康元药业集团股份有限公司2022年第三季度报告（英文版）
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2022 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there are no false representations, misleading statements or material omissions contained in this announcement and accept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this quarterly report, and that there are no false representations, misleading statements or material omissions contained herein, and severally and jointly accept legal responsibility. ? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the third quarterly financial statements are audited. □Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Date and Financial Indicators
Unit: Yuan Currency: RMB
| Item | For the Reporting
Period | YoY change (%) | From the
beginning of the
year to the end of
the Reporting
Period | YoY change (%) | | Revenue | 4,447,021,452.61 | 8.51 | 13,011,966,738.16 | 9.04 | | Net profit attributable to
shareholders of the listed
company | 325,293,433.73 | 1.23 | 1,126,561,953.23 | 11.69 | | Net profit attributable to
shareholders of the listed
company after deduction of
extraordinary gains and losses | 312,360,089.27 | -2.90 | 1,116,354,521.30 | 21.40 | | Net cash flow from operating
activities | N/A | N/A | 2,608,992,532.97 | 60.93 | | Basic earnings per share
(RMB/share) | 0.1748 | 6.61 | 0.5983 | 16.09 | | Diluted earnings per share
(RMB/share) | 0.1739 | 6.19 | 0.5971 | 16.13 | | Weighted average return on
net assets (%) | 2.74 | Decreased by 0.11
percentage points | 9.39 | Increased by 0.50
percentage points | | | As at the end of the
Reporting Period | As at the end of the previous year | YoY change (%) | | | Total assets | 34,713,695,364.54 | 31,103,900,389.29 | 11.61 | | | Owner's equity attributable to
shareholders of the listed
company | 12,900,492,209.56 | 11,820,293,656.69 | 9.14 | |
Notes: 1. The “Reporting Period” represents the 3-month period from the beginning to the end of this quarter,
the same below.
2. From July to September 2022, the Company realized net profit attributable to shareholders of the
parent of RMB325 million, of which Joincare excluding Livzon Pharmaceutical Group Inc. (“Livzon Group”)
and Livzon MAB Pharm Inc. (“Livzon MAB”) realized net profit attributable to shareholders of the parent of
approximately RMB217 million, representing a YoY increase of approximately 37%, and the impact of Livzon
MAB on the net profit attributable to shareholders of the parent was approximately negative RMB186 million.
From January to September 2022, the Company realized net profit attributable to shareholders of the parent of
RMB1,127 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized net profit attributable to shareholders of the parent of approximately RMB638 million, representing a YoY increase of
approximately 42%, and the impact of Livzon MAB on the net profit attributable to shareholders of the parent
was approximately negative RMB325 million.
3. From January to September 2022, the Company realized revenue of RMB7,402 million from chemical pharmaceuticals, representing a YoY increase of 7.16%, among which, RMB862 million were from
respiratory formulation, representing a YoY increase of 215%; RMB1,151 million were from anti-infective
products, representing a YoY increase of 9.29%; RMB2,646 million were from gastroenterology products,
representing a YoY decrease of 11.60%; RMB2,092 million were from gonadotropic hormones, representing a
YoY increase of 5.81% and RMB400 million were from psychiatry products, representing a YoY increase of
30.68%. The Company realized revenue of RMB4,054 million from APIs and intermediates, representing a
YoY increase of 17.80%. The Company realized revenue of RMB864 million from traditional Chinese medicine, representing a YoY increase of 1.28%. The Company realized revenue of RMB502 million from
diagnostic reagents and equipment, representing a YoY decrease of 9.09%. The Company realized revenue of
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
| Item | For the Reporting
Period | From the beginning of the
year to the end of the
Reporting Period | | Gain or loss on disposal of non-current assets | 1,429,336.99 | 5,161,222.54 | | Government grants recognized in profit or loss for the current
period (excluding government grants that are closely related to
the ordinary operating business of the Company and are
provided in fixed amount or quantity continuously according to
the applicable polices and standards of the country) | 45,982,790.93 | 140,167,993.52 | | Gains and losses on fair value changes incurred from financial
assets held for trading, derivative financial assets, financial
liabilities held for trading and derivative financial liabilities, and
investment income on disposal of financial assets held for
trading, derivative financial assets, financial liabilities held for
trading, derivative financial liabilities and other debt
investments, except for effective hedging activities related to the
ordinary operating business of the Company | -14,007,798.34 | -112,944,327.05 | | Reversal of provision for impairment of accounts receivable and
contract assets tested for impairment individually | 0.00 | 158,470.77 | | Other non-operating income and expenses apart from the above
items | -6,269,628.08 | -8,540,320.05 | | Less: Effect of income tax | -330,154.62 | 10,109,361.17 | | Effect of minority equity (after tax) | 14,531,511.66 | 3,686,246.63 | | Total | 12,933,344.46 | 10,207,431.93 |
Explanations for classifying items of extraordinary gains and losses defined in the Explanatory Announcement No. 1 for Public Company Information Disclosures –Non-recurring Profits and Losses as
items of recurring profit or loss
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Therefor √Applicable □N/A
| Item | Change (%) | Main reasons | | Net cash flow from
operating activities | 60.93 | Mainly due to an increase of cash
collections of sales revenues. |
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons Therefor
| Balance Sheet | 30 September
2022 | 31 December
2021 | Change in
proportion
（%） | Main Reason | | Financial assets held
for trading | 121,394,233.59 | 184,638,344.31 | -34.25 | Primarily due to fluctuations in
market value of the securities
investment held. | | Other receivables | 51,182,462.61 | 88,053,825.12 | -41.87 | Mainly due to the receipt of
payment during the current
period. | | Non-current assets due
within one year | 38,498.84 | 317,381.23 | -87.87 | Primarily due to the recovery of
finance lease payments. | | Other current assets | 28,941,853.23 | 83,986,214.37 | -65.54 | Primarily due to the decrease in
the amount of VAT credits as a
result of the refund thereof and
the prepaid income tax has
transferred out. | | Long-term receivables | 82,574.69 | 266,904.13 | -69.06 | Primarily due to the recovery of
finance lease payments. | | Financial liabilities
held for trading | 23,888,725.35 | 143,302.24 | 16570.17 | Primarily due to fluctuations in
fair value of foreign exchange
forward contract | | Contract liabilities | 85,390,395.48 | 234,140,702.29 | -63.53 | Primarily due to some contract
performance obligations during
the current period, which
satisfies the conditions for
revenue recognition and results
in the carrying forward of
revenue. | | Taxes payable | 356,093,489.85 | 270,618,183.41 | 31.59 | Primarily due to the increase in
corporate income tax payable. | | Non-current liabilities
due within one year | 19,385,099.93 | 91,576,066.33 | -78.83 | Mainly due to an increase of
repayment of long-term
borrowings. | | Other current liabilities | 5,977,716.75 | 15,626,224.29 | -61.75 | Primarily due to the decrease in
pending output tax as the
contract payment collected in
advance in the current period
meets the revenue recognition
conditions and is carried forward. | | Long-term loans | 3,028,666,590.94 | 826,780,252.78 | 266.32 | Mainly due to an addition to
long-term borrowings during the
current period. | | Other comprehensive
income | 37,371,610.95 | 5,387,545.97 | 593.67 | Mainly due to change of
exchange differences on
translation of statements as a
result of fluctuation in exchange
rate. | | Statement of Income | January to
September for
2022 | January to
September for
2021 | Change in
proportion
（%） | Main Reason | | Financial expenses | -330,371,807.68 | -43,302,001.92 | N/A | Mainly due to the deposit interest
during the current period is
higher than last period and the | | | | | | exchange gains arising from
fluctuation in exchange rate. | | Income from
investments (loss is
indicated by“-”) | 48,386,584.36 | 69,260,277.50 | -30.14 | Primarily due to a decrease in
dividend for the current period,
together with fluctuation in
exchange rate and losses from
settlement of the forward foreign
exchange contract business. | | Gains from changes in
fair values (loss is
indicated by“-”) | -86,989,533.83 | -18,014,545.96 | N/A | Primarily due to fluctuations in
market value of the securities
investment held. | | Impairment loss of
assets (loss is indicated
by“-”) | -142,159,872.24 | -35,798,711.62 | N/A | Primarily due to the impairment
provision for inventories for the
current period is higher than last
period. | | Gains from disposal of
assets (loss is indicated
by“-”) | 1,121,679.66 | 18,357,859.21 | -93.89 | Mainly due to gains from transfer
of land use rights during last
period. | | Cash Flow Statement | January to
September for
2022 | January to
September for
2021 | Change in
proportion
（%） | Main Reason | | Net cash flow from
operating activities | 2,608,992,532.97 | 1,621,169,704.58 | 60.93 | Mainly due to an increase of cash
collections of sales revenues for
the current period. | | Net cash flow from
investing activities | -886,929,197.44 | -1,509,334,937.50 | N/A | Mainly due to the combination of
cash collection through selling
equity and the additional
investment for last period. | | Net cash flow from
financing activities | 873,841,344.96 | -1,783,771,890.06 | N/A | Mainly due to the further
borrowings and capital raised
(issuance of GDRs) for the
current period. |
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary
shares as of the end of the Reporting
Period | 96,795 | Total number of holders of preferred
shares with restored voting rights as of
the end of the Reporting Period (if any) | 0 | | | | | Shareholdings of the top 10 shareholders | | | | | | | | Name of shareholder | Nature of
shareholder | Number of
shares held | Percentage
(%) | Number of
shares held
with selling
restrictions | Pledge, mark or lock-up | | | | | | | | Share
status | Number | | Shenzhen Baiyeyuan Investment Co.,
Ltd. (深圳市百业源投资有限公司) | Domestic non-
state-owned
entity | 878,272,753 | 45.56 | 0 | Pledge | 95,679,725 | | Hong Kong Securities Clearing Company
Limited | Unknown | 130,019,561 | 6.74 | 0 | Unknown | | | Citibank, National Association | Unknown | 63,825,000 | 3.31 | 0 | Unknown | | | Might Seasons Limited | Foreign entity | 57,487,434 | 2.98 | 0 | Unknown | | | Huaxia Life Insurance Co., Ltd. - Own
fund | Unknown | 9,275,718 | 0.48 | 0 | Unknown | | | He Zhong | Domestic
natural person | 7,800,024 | 0.40 | 0 | Unknown | | | Abu Dhabi Investment Authority (阿布达
比投资局) | Foreign entity | 6,334,742 | 0.33 | 0 | Unknown | | | Joincare Pharmaceutical Group Industry
Co., Ltd. — the Second Phase Ownership
Scheme under Medium to Long-term
Business Partner Share Ownership
Scheme (健康元药业集团股份有限公司
－中长期事业合伙人持股计划之第二
期持股计划) | Others | 6,275,372 | 0.33 | 0 | - | | | 16011 portfolio of basic endowment
insurance fund | Unknown | 5,867,634 | 0.30 | 0 | Unknown | | | Agricultural Bank of China Limited - CSI
500 Exchange Traded Index Securities
Investment Fund | Unknown | 5,480,994 | 0.28 | 0 | Unknown | | | Shareholdings of the top 10 shareholders without selling restrictions | | | | | | | | Name of shareholder | Number of tradable shares held
without selling restrictions | Class and number of shares | | | | | | | | Class of shares | Number | | | | | Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源
投资有限公司) | 878,272,753 | Ordinary shares
denominated in
Renminbi | 878,272,753 | | | | | Hong Kong Securities Clearing Company Limited | 130,019,561 | Ordinary shares
denominated in
Renminbi | 130,019,561 | | | | | Citibank, National Association | 63,825,000 | Ordinary shares
denominated in
Renminbi | 63,825,000 | | | | | Might Seasons Limited | 57,487,434 | Ordinary shares
denominated in
Renminbi | 57,487,434 | | | | | Huaxia Life Insurance Co., Ltd. - Own fund | 9,275,718 | Ordinary shares
denominated in
Renminbi | 9,275,718 | | | | | He Zhong | 7,800,024 | Ordinary shares
denominated in
Renminbi | 7,800,024 | | | | | Abu Dhabi Investment Authority (阿布达比投资局) | 6,334,742 | Ordinary shares
denominated in
Renminbi | 6,334,742 | | | | | Joincare Pharmaceutical Group Industry Co., Ltd. — the
Second Phase Ownership Scheme under Medium to Long-
term Business Partner Share Ownership Scheme (健康元药
业集团股份有限公司－中长期事业合伙人持股计划之第
二期持股计划) | 6,275,372 | Ordinary shares
denominated in
Renminbi | 6,275,372 | | | | | 16011 portfolio of basic endowment insurance fund | 5,867,634 | Ordinary shares
denominated in
Renminbi | 5,867,634 | | | | | Agricultural Bank of China Limited - CSI 500 Exchange
Traded Index Securities Investment Fund | 5,480,994 | Ordinary shares
denominated in
Renminbi | 5,480,994 | | | | | Description of connection or acting-in-concert relationship
of the above shareholders | There was no connection or acting-in-concert relationship between
Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the
Company, and other shareholders; whether there is connection or acting-in-
concert relationship among other shareholders is unknown | | | | | |
| Description of the participation of the top 10 shareholders
and the top 10 shareholders without selling restrictions in
margin financing and securities lending and refinancing
business (if any) | As of the end of the Reporting Period, the number of the shares lent from
Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the
Company, through participation in refinancing is 17,380,900, without any
transfer of ownership.
He Zhong, a shareholder, holds a total of 7,800,024 shares of the Company,
including 800,000 shares held through ordinary securities accounts and
7,000,024 shares held through credit securities accounts. | | Description of the special repurchase account among the
top 10 shareholders | As of the end of the Reporting Period, the special repurchase account of the
Company (special securities repurchase account of Joincare Pharmaceutical
Group Industry Co., Ltd.) owned 17,459,813 shares in total, accounting for
0.91%. |
Note: Citibank, National Association is the depositary of the Company’s GDRs, the corresponding domestic
basic A Shares of GDRs shall registered under its name according to the laws; the GDRs issued by the Company
shall be not converted into A Shares from 26 September 2022 (Switzerland Time) to 23 January 2023 (Switzerland Time).
III. OTHER REMINDERS
Other important information that needs to be brought to the attention of investors regarding the Company’s operations during the Reporting Period
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
30 September 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 30 September 2022 | 31 December 2021 | | Current assets: | | | | Monetary funds | 14,574,355,344.50 | 11,729,230,390.98 | | Financial assets held for trading | 121,394,233.59 | 184,638,344.31 | | Bill receivable | 1,761,732,574.61 | 1,977,286,022.02 | | Accounts receivable | 3,348,701,858.06 | 2,853,655,551.54 | | Receivables financing | | | | Prepayments | 390,858,423.43 | 369,232,546.29 | | Other receivables | 51,182,462.61 | 88,053,825.12 | | In which: Interests receivable | | 365,873.64 | | Dividends receivable | | | | Inventories | 2,293,286,563.09 | 2,078,944,387.68 | | Contract assets | | | | Held-for-sale assets | | | | Non-current assets due within one year | 38,498.84 | 317,381.23 | | Other current assets | 28,941,853.23 | 83,986,214.37 | | Total current assets | 22,570,491,811.96 | 19,365,344,663.54 | | Non-current assets: | | | | Debt investment | | | | Other debt investment | | | | Long-term receivables | 82,574.69 | 266,904.13 | | Long-term equity investment | 1,445,516,030.89 | 1,419,349,454.84 | | Other equity instrument investment | 1,202,246,220.39 | 1,408,882,377.42 | | Other non-current financial assets | | | | Investment properties | 6,191,475.43 | 6,191,475.43 | | Fixed assets | 5,031,567,135.95 | 4,839,005,169.81 | | Construction in progress | 914,020,725.38 | 742,998,743.75 | | Productive biological assets | | | | Oil & gas assets | | | | Right-of-use assets | 41,072,299.34 | 46,774,759.69 | | Intangible assets | 507,221,484.83 | 456,782,094.80 | | Development expenses | 803,845,060.85 | 786,993,435.71 | | Goodwill | 614,468,698.73 | 614,468,698.73 | | Long-term prepaid expenses | 248,031,970.13 | 200,715,740.93 | | Deferred income tax assets | 599,351,023.48 | 552,542,866.71 | | Other non-current assets | 729,588,852.49 | 663,584,003.80 | | Total non-current assets | 12,143,203,552.58 | 11,738,555,725.75 | | Total assets | 34,713,695,364.54 | 31,103,900,389.29 | | Current liabilities: | | | | Short-term loans | 2,355,133,620.36 | 2,518,484,835.09 | | Financial liabilities held for trading | 23,888,725.35 | 143,302.24 | | Notes payable | 1,704,031,516.46 | 1,582,386,767.93 | | Accounts payable | 875,494,946.90 | 871,553,210.51 | | Receipts in advance | | | | Contract liabilities | 85,390,395.48 | 234,140,702.29 | | Payroll payable | 422,866,738.80 | 475,430,823.20 | | Taxes payable | 356,093,489.85 | 270,618,183.41 | | Other payables | 3,629,808,271.81 | 3,292,407,989.79 | | In which: Interests payable | | | | Dividends payable | 14,009,877.69 | 6,951,984.46 | | Held-for-sale liabilities | | | | Non-current liabilities due within one year | 19,385,099.93 | 91,576,066.33 | | Other current liabilities | 5,977,716.75 | 15,626,224.29 | | Total current liabilities | 9,478,070,521.69 | 9,352,368,105.08 | | Non-current liabilities: | | | | Long-term loans | 3,028,666,590.94 | 826,780,252.78 | | Bonds payable | | | | Lease liabilities | 22,778,162.56 | 25,071,794.32 | | Long-term payables | | | | Long-term payroll payable | | | | Estimated liabilities | | | | Deferred income | 458,651,827.54 | 433,543,352.40 | | Deferred income tax liabilities | 191,906,813.07 | 208,525,905.39 | | Other non-current liabilities | 84,000,000.00 | 78,000,000.00 | | Total non-current liabilities | 3,786,003,394.11 | 1,571,921,304.89 | | Total liabilities | 13,264,073,915.80 | 10,924,289,409.97 | | Owner's equity (or shareholder's equity): | | | | Paid-in capital | 1,927,655,269.00 | 1,907,727,908.00 | | Other equity instruments | | | | In which: Preferred shares | | | | Perpetual debts | | | | Capital reserve | 2,358,462,480.42 | 2,265,357,311.92 | | Less: Treasury shares | 222,644,454.50 | 222,644,454.50 | | Other comprehensive income | 37,371,610.95 | 5,387,545.97 | | Special reserve | | | | Surplus reserve | 649,438,942.77 | 640,821,179.08 | | Undistributed profits | 8,150,208,360.92 | 7,223,644,166.22 | | Total owner's equity (or shareholder's equity)
attributable to the parent company | 12,900,492,209.56 | 11,820,293,656.69 | | Minority shareholder's equity | 8,549,129,239.18 | 8,359,317,322.63 | | Total owner's equity (or shareholder's equity) | 21,449,621,448.74 | 20,179,610,979.32 | | Total liabilities and owner's equity (or
shareholder's equity) | 34,713,695,364.54 | 31,103,900,389.29 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company's accounting work: accounting department: Qiu Qiu Qingfeng Qingfeng
Consolidated Income Statement
From January to September, 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters
(January to
September) for 2022 | First three
quarters (January
to September) for
2021 | | I. Total revenue | 13,011,966,738.16 | 11,933,648,988.85 | | In which: Operating revenue | 13,011,966,738.16 | 11,933,648,988.85 | | II. Total operating costs | 10,347,452,908.46 | 9,728,395,382.69 | | In which: Operating costs | 4,590,752,440.39 | 4,202,628,262.24 | | Operating tax and surcharges | 148,072,490.55 | 138,588,360.34 | | Selling expenses | 3,893,351,191.76 | 3,820,420,328.92 | | Administrative expenses | 813,143,493.11 | 651,003,507.97 | | R&D expenses | 1,232,505,100.33 | 959,056,925.14 | | Financial expenses | -330,371,807.68 | -43,302,001.92 | | In which: Interest expenses | 95,844,022.98 | 73,581,421.29 | | Interest income | 296,268,948.39 | 111,786,015.39 | | Add: Other income | 142,661,731.19 | 177,015,688.29 | | Income from investments (loss is indicated by“-”) | 48,386,584.36 | 69,260,277.50 | | In which: Income from investments in associates and
joint ventures | 52,468,548.10 | 11,789,322.81 | | Gains from derecognition of financial assets at
amortized cost | | | | Gains from net exposure hedges (loss is indicated
by“-”) | | | | Gains from changes in fair values (loss is indicated
by“-”) | -86,989,533.83 | -18,014,545.96 | | Losses of credit impairment (loss is indicated by“-”) | -9,508,656.53 | -10,549,870.63 | | Impairment loss of assets (loss is indicated by“-”) | -142,159,872.24 | -35,798,711.62 | | Gains from disposal of assets (loss is indicated by“-”) | 1,121,679.66 | 18,357,859.21 | | III. Operating profit (loss is indicated by“-”) | 2,618,025,762.31 | 2,405,524,302.95 | | Add: Non-operating income | 4,995,275.26 | 5,662,349.74 | | Less: Non-operating expenses | 13,738,456.89 | 19,120,502.95 | | IV. Total profit (loss is indicated by“-”) | 2,609,282,580.68 | 2,392,066,149.74 | | Less: Income tax expenses | 408,012,299.49 | 316,486,740.44 | | V. Net profit (loss is indicated by“-”) | 2,201,270,281.19 | 2,075,579,409.30 | | (I) Classified by business continuity | | | | 1. Net profit from ongoing operation (loss is indicated
by“-”) | 2,201,270,281.19 | 2,075,579,409.30 | | 2. Net profit from discontinuing operation (loss is
indicated by“-”) | | | | (II) Classified by ownership | | | | 1.Net profit attributable to shareholders of the parent
company (loss is indicated by“-”) | 1,126,561,953.23 | 1,008,675,184.73 | | 2.Profit and loss of minority shareholders (loss is
indicated by“-”) | 1,074,708,327.96 | 1,066,904,224.57 | | VI. Other comprehensive income, net of tax | 80,412,282.94 | -177,089,388.22 | | (I) Other comprehensive income attributable to owners of
the parent company, net of tax | 31,984,064.97 | -90,541,944.15 | | 1. Other comprehensive income that cannot be
reclassified into profit or loss | 12,029,097.03 | -55,197,967.72 | | (1) Changes from remeasurement of defined benefit
plans | | | | (2) Other comprehensive income that cannot be
reclassified into profit or loss under the equity method | 1,173,144.60 | -3,992,639.64 | | (3) Changes in fair value of investments in other equity
instruments | 10,855,952.43 | -51,205,328.08 | | (4) Changes in fair value of the enterprise's own credit
risks | | | | 2. Other comprehensive income that will be reclassified
into profit or loss | 19,954,967.94 | -35,343,976.43 | | (1) Other comprehensive income that can be reclassified
into profit or loss under the equity method | | | | (2) Changes in fair value of other debt investments | | | | (3) Amount of financial assets reclassified into other
comprehensive income | | | | (4) Provision for credit impairment of other debt
investments | | | | (5) Reserve for cash flow hedges | | | | (6) Exchange differences on translation of financial
statements denominated in foreign currencies | 19,954,967.94 | -35,343,976.43 | | (7) Others | | | | (II) Other comprehensive income attributable to minority
shareholders, net of tax | 48,428,217.97 | -86,547,444.07 | | VII. Total comprehensive income | 2,281,682,564.13 | 1,898,490,021.08 | | (I) Total comprehensive income attributable to owners of
the parent company | 1,158,546,018.20 | 918,133,240.58 | | (II) Total comprehensive income attributable to minority
shareholders | 1,123,136,545.93 | 980,356,780.50 | | VIII. Earnings per share: | | | | (I) Basic earnings per share (RMB/share) | 0.5983 | 0.5154 | | (II) Diluted earnings per share (RMB/share) | 0.5971 | 0.5142 |
（未完）
|
|
